Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bunte

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
European Journal of Neurology|August 8, 2023
A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosisDaphne N Weemering, Mark Midei, Peter Milner, et al.
Scientific Reports|November 22, 2023
Plant-based production of a protective vaccine antigen against the bovine parasitic nematode Ostertagia ostertagiLaurens Zwanenburg, Jimmy Borloo, Bregt Decorte, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 24, 2021
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating proceduresJaap N E Bakers, Adriaan D de Jongh, Tommy M Bunte, et al.
Blood|October 11, 2007
Targeting Notch signaling in autoimmune and lymphoproliferative diseaseDavid T Teachey, Alix E Seif, Valerie I Brown, et al.
Neurology|June 13, 2023
Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALSAdriaan D de Jongh, Ruben P A van Eijk, Leonhard A Bakker, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 6, 2025
Respiratory measurements, respiratory symptoms, and quality of life in ALS: results from the REVEALS studyDeirdre Murray, James Rooney, Dara Meldrum, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Science Translational Medicine|August 9, 2013
Genome-wide mutational signatures of aristolochic acid and its application as a screening toolSong Ling Poon, See-Tong Pang, John R McPherson, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
European Journal of Neurology|August 8, 2023
A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosisDaphne N Weemering, Mark Midei, Peter Milner, et al.
Scientific Reports|November 22, 2023
Plant-based production of a protective vaccine antigen against the bovine parasitic nematode Ostertagia ostertagiLaurens Zwanenburg, Jimmy Borloo, Bregt Decorte, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 24, 2021
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating proceduresJaap N E Bakers, Adriaan D de Jongh, Tommy M Bunte, et al.
Blood|October 11, 2007
Targeting Notch signaling in autoimmune and lymphoproliferative diseaseDavid T Teachey, Alix E Seif, Valerie I Brown, et al.
Neurology|June 13, 2023
Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALSAdriaan D de Jongh, Ruben P A van Eijk, Leonhard A Bakker, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 6, 2025
Respiratory measurements, respiratory symptoms, and quality of life in ALS: results from the REVEALS studyDeirdre Murray, James Rooney, Dara Meldrum, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trialsAngela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
Science Translational Medicine|August 9, 2013
Genome-wide mutational signatures of aristolochic acid and its application as a screening toolSong Ling Poon, See-Tong Pang, John R McPherson, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Pageof 8